and there 2009 report says:

"Prosavin currently has shown a stable approximate 30% improvement in the patient's condition, regardless of dose level. At 30% improvement in larger trials it will likely challenge deep brain stimulation for the surgery market in Parkinson's disease".

So not a cure, still early days, (Spheramine failed much later than the stage at which Prosavin is currently), and Oxfordbiomedica see Prosavin as coming to market 2012/2013, if it passes trials and they get a partner as they cannot afford this to go alone, etc, yadda yadda ...

Remember, they all work on monkeys and rats and until the tests are blinded, (at this rate I might have that on my gravestone).

Sorry, just trying to spread a little realism here.

Neil (aka misery of Evesham).